Mark Lappe, Chief Executive Officer of Inhibrx Biosciences, Inc. (INBX), made a significant purchase of company stock on September 8, 2026. Lappe acquired 9,681 shares at an average price of $112.28 per share, representing a total investment of approximately $1.09 million.
This transaction by a senior executive is often interpreted as a signal of strong confidence in the company's future prospects. Lappe's substantial buy-in underscores his personal conviction in Inhibrx Biosciences' strategic direction and growth potential.
The purchase occurred alongside other insider buying activity, including a transaction by Douglas Forsyth. These collective insider purchases may be viewed positively by the market as an indication of internal belief in the company's value.